Key result
The adequacy of surrogate markers to assess cardiovascular disease drugs could not be evaluated because the abstract contains only website boilerplate text.
Answers are grounded in this paper and cite their sources.
No conclusion possible from this review; leaves open surrogate marker adequacy for cardiovascular drugs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Robert Temple (1999) conducted an editorial in Cardiovascular Disease. Surrogate markers was evaluated. The adequacy of surrogate markers to assess cardiovascular disease drugs could not be evaluated because the abstract contains only website boilerplate text.
Synapse has enriched 10 related papers. Consider them for comparative context: